Context Therapeutics Inc.
For the period ended Sep 30, 2025. Filed Nov 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 5, 2025
CNTX$0.19-6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
| Nine Months Ended September 30, 2025 | |||||
|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · TotalStockholders’Equity | |||||
| Shares · Amount | |||||
| Balance at January 1, 2025 | 89,704,194 | $89,704 | $189,956,252 | $(94,779,694) | $95,266,262 |
| Share-based compensation expense | — | — | 293,717 | — | 293,717 |
| Net loss | — | — | — | (4,577,261) | (4,577,261) |
| Balance at March 31, 2025 | 89,704,194 | 89,704 | 190,249,969 | (99,356,955) | 90,982,718 |
| Share-based compensation expense | — | — | 389,114 | — | 389,114 |
| Net loss | — | — | — | (8,827,510) | (8,827,510) |
| Balance at June 30, 2025 | 89,704,194 | 89,704 | 190,639,083 | (108,184,465) | 82,544,322 |
| Exercise of pre-funded warrants from private placement | 2,174,983 | 2,175 | (2,175) | — | — |
| Share-based compensation expense | — | — | 323,081 | — | 323,081 |
| Net loss | — | — | — | (9,693,237) | (9,693,237) |
| Balance at September 30, 2025 | 91,879,177 | $91,879 | $190,959,989 | $(117,877,702) | $73,174,166 |
| Nine Months Ended September 30, 2024 | |||||
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · TotalStockholders’Equity | |||||
| Shares · Amount | |||||
| Balance at January 1, 2024 | 15,966,053 | $15,966 | $79,909,644 | $(68,054,590) | $11,871,020 |
| Share-based compensation expense | — | — | 240,007 | — | 240,007 |
| Net loss | — | — | — | (3,667,797) | (3,667,797) |
| Balance at March 31, 2024 | 15,966,053 | 15,966 | 80,149,651 | (71,722,387) | 8,443,230 |
| Sale of common stock and prefunded warrants, net of offering costs of $5,234,020 | 59,032,259 | 59,032 | 94,699,715 | — | 94,758,747 |
| Share-based compensation expense | — | — | 157,037 | — | 157,037 |
| Net loss | — | — | — | (2,254,506) | (2,254,506) |
| Balance at June 30, 2024 | 74,998,312 | 74,998 | 175,006,403 | (73,976,893) | 101,104,508 |
| Share-based compensation expense | — | — | 213,002 | — | 213,002 |
| Net loss | — | — | — | (17,459,893) | (17,459,893) |
| Balance at September 30, 2024 | 74,998,312 | $74,998 | $175,219,405 | $(91,436,786) | $83,857,617 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.